Market Place
Sourcing Support
NeoImmuneTech Presents CAR-T Combo Data With NT-I7 At ESMO 2024
09 Sep 2024 //
PR NEWSWIRE
NeoImmuneTech: EMA Orphan Drug For NT-I7 In Acute Radiation Syndrome
04 Jun 2024 //
PR NEWSWIRE
NeoImmuneTech`s NT-I7 Plus CPI Combo Benefits In Immuno-Oncology
03 Jun 2024 //
PR NEWSWIRE
NeoImmuneTech`s NT-I7 + Chemo Effective In Colorectal Cancer
09 Apr 2024 //
PR NEWSWIRE
NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
02 Apr 2024 //
PR NEWSWIRE
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech`s NT-I7
30 Jan 2024 //
PR NEWSWIRE
NeoImmuneTech Welcomes a New President for its Development and Business
15 Jan 2024 //
PR NEWSWIRE
NeoImmuneTech and Imugene enter into strategic research collaboration
11 Dec 2023 //
PR NEWSWIRE
FDA Grants Orphan Drug Designation to NeoImmuneTech`s NT-I7
20 Nov 2023 //
PR NEWSWIRE
NeoImmuneTech to Present New Advances on NT-I7 at 2023 SITC Annual Meeting
27 Sep 2023 //
PR NEWSWIRE
NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board
25 Jul 2023 //
PR NEWSWIRE
NeoImmuneTech to Partner with NIAID, NIH for Drug Development in (ARS)
03 Jan 2023 //
PR NEWSWIRE
New evidence of NeoImmuneTech`s NT-I7 clinical efficacycombination pembrolizumab
11 Nov 2022 //
PRNEWSWIRE
NeoImmuneTech to Present Data on NT-I7 in Combo with CAR-T tisagenlecleucel
04 Nov 2022 //
PRNEWSWIRE
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at SITC
05 Oct 2022 //
PRNEWSWIRE
NeoImmuneTech`s NT-I7 Creates a ITM with Pembrolizumab
12 Sep 2022 //
PRNEWSWIRE
NeoImmuneTech Welcomes New Members to its Scientific Advisory Board
08 Aug 2022 //
PRNEWSWIRE
FDA Grants ODD Status to NeoImmuneTech`s NT-I7 for Glioblastoma Multiforme
13 Jul 2022 //
PRNEWSWIRE
NeoImmuneTech drug could reduce CAR-T cells needed fivefold
16 Jun 2022 //
FIERCEBIOTECH
NeoImmuneTech`s NT-I7 Enhances CAR-T Cell Expansion and Anti-tumor Activity
14 Jun 2022 //
PRNEWSWIRE
NeoImmuneTech to Present at Upcoming BIO International Convention
13 Jun 2022 //
PRNEWSWIRE
NeoImmuneTech`s Lead Asset NT-I7 Shows Preliminary Anticancer Activity
06 Jun 2022 //
PRNEWSWIRE
NeoImmuneTech to Show Significant Advances on NT-I7 at 2022 ASCO
27 Apr 2022 //
BUSINESSWIRE
NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential at AACR
13 Apr 2022 //
BUSINESSWIRE
NeoImmuneTech to Present Two Posters at AACR 2022
10 Mar 2022 //
BUSINESSWIRE
NeoImmuneTech Begins Dosing in Phase 2 Study of NT-I7+PD-L1 Checkpoint Inhibitor
07 Feb 2022 //
BUSINESSWIRE
Preclinical Data on NT-I7 Published in Clinical Cancer Research
24 Jan 2022 //
BUSINESSWIRE
NeoImmuneTech Presents Ph1 Study Data at Society Neuro-Oncology
23 Nov 2021 //
BUSINESSWIRE
NeoImmuneTech Presents Phase 1 Study Data at SNO 2021
22 Nov 2021 //
BUSINESSWIRE
NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer
25 Aug 2021 //
BUSINESSWIRE
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7
26 Jul 2021 //
BUSINESSWIRE
NeoImmuneTech To begin Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo
08 Jun 2021 //
BUSINESSWIRE
NeoImmuneTech Trial Data Presented at ASCO Annual Meeting
07 Jun 2021 //
BUSINESSWIRE
NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7
24 May 2021 //
BIOSPACE
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7
30 Mar 2021 //
BUSINESSWIRE
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7
30 Mar 2021 //
BUSINESSWIRE
NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion
23 Mar 2021 //
BUSINESSWIRE
NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study
23 Mar 2021 //
BUSINESSWIRE
NeoImmuneTech Announces Closing of Initial Public Offering
16 Mar 2021 //
BUSINESSWIRE
US FDA clears NeoImmuneTech’s IND application for NT-I7
25 Feb 2021 //
PHARMBIZ
NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7
23 Feb 2021 //
BUSINESSWIRE
NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7
23 Feb 2021 //
BUSINATSSWIRE
NeoImmuneTech Announces First Patient Dosed in Phase 1 Study of NT-I7
30 Nov 2020 //
BUSINESSWIRE
NeoImmuneTech Announces First Patient Dosed in Phase 1 Study of NT-I7
29 Nov 2020 //
BUSINESSWIRE
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7
16 Nov 2020 //
BUSINESSWIRE
Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study
10 Nov 2020 //
BIOSPACE
NeoImmuneTech Announces a Second Clinical Collaboration with Roche
22 Oct 2020 //
BUSINESSWIRE
NeoImmuneTech Announces a Second Clinical Collab with Roche to Evaluate NT-I7
21 Oct 2020 //
BUSINESSWIRE
FDA clears NeoImmuneTech’s IND for combination therapy to treat B-cell lymphoma
25 Aug 2020 //
PHARMABIZZ
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7
24 Aug 2020 //
BUSINESSWIRE
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study
24 Aug 2020 //
BUSINESSWIRE
NeoImmuneTech Announces Receipt of IND Clearance Trial of NT-I7
27 Jul 2020 //
BUSINESSWIRE
NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Ph 2 of NT-I7
20 Jul 2020 //
BUSINESSWIRE
NeoImmuneTech Receives U.S. FDA Clearance of IND for Ph2 Study of NT-I7
20 Jul 2020 //
BIOSPACE
NeoImmuneTech Announces Clearance for iNDA of NT-I7 (efineptakin alfa)
15 Jul 2020 //
BUSINESSWIRE
NeoImmuneTech Announces Clearance for Investigational NDA of NT-I7
14 Jul 2020 //
BUSINESSWIRE
Duodenal Mucosal Resurfacing Elicits Improvement in Glycemic & Parameters
24 Jun 2020 //
DIABETESJOURNALS
NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7
24 Jun 2020 //
BUSINESSWIRE
NeoImmuneTech Receives FDA Orphan Drug Designation for NT-I7 (efineptakin alfa)
15 Jun 2020 //
BUSINESSWIRE
NeoImmuneTech Announces Clinical Collaboration with BMY`s to Evaluate NT-I7
09 Apr 2020 //
BUSIBNESSWIRE
